# Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
**Date:** 2026-01-20 16:00:00
**Company:** Vertex Pharmaceuticals Incorporated
**Ticker:** VRTX
**Source URL:** https://www.businesswire.com/news/home/20260120813466/en/Vertex-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-12th/
---
Jan 20, 2026 4:00 PM Eastern Standard Time
# **Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th**
Share
* * *
BOSTON--( [BUSINESS WIRE](https://www.businesswire.com/))-- [Vertex Pharmaceuticals Incorporated](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vrtx.com&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=5c361d0af6a381cf14e95081825adf63) (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a c...
# Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
**Date:** 2026-01-20 16:00:00
**Company:** Vertex Pharmaceuticals Incorporated
**Ticker:** VRTX
**Source URL:** https://www.businesswire.com/news/home/20260120813466/en/Vertex-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-12th/
---
Jan 20, 2026 4:00 PM Eastern Standard Time
# **Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th**
Share
* * *
BOSTON--( [BUSINESS WIRE](https://www.businesswire.com/))-- [Vertex Pharmaceuticals Incorporated](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vrtx.com&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=5c361d0af6a381cf14e95081825adf63) (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.”
The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at [www.vrtx.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com%2F&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=www.vrtx.com&index=2&md5=c52074854c38c0587746ccc1323e05ac) in the “Investors” section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.
**About Vertex**
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit [www.vrtx.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com%2F&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=www.vrtx.com&index=3&md5=ecdea4ae8b5e1e19bc0bf88a3d0bdcc4) or follow us on [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvertex-pharmaceuticals%2F&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=LinkedIn&index=4&md5=755ea1de2551c41b6b244c22a04f79e5), [Facebook](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FVertexPharmaInc&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=Facebook&index=5&md5=993a4ca6d7e65aef619716575349ca0c), [Instagram](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fvertexpharmaceuticals%2F&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=Instagram&index=6&md5=ecee34c2882372350118d7426663690e), [YouTube](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40Vertex-Pharmaceuticals&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=YouTube&index=7&md5=9e1ee3303b5f16576bfd0520e529f666) and [X](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FVertexPharma&esheet=54400169&newsitemid=20260120813466&lan=en-US&anchor=X&index=8&md5=37824555d4a4c9fb0e35a06cf1423cac).
(VRTX-WEB)
## Contacts
**Vertex Pharmaceuticals Incorporated Investor Relations:**
[investorinfo@vrtx.com](mailto:investorinfo@vrtx.com)
Industry:
- [Research](https://www.businesswire.com/newsroom?industry=1000159)
- [Medical Devices](https://www.businesswire.com/newsroom?industry=1000110)
- [Diabetes](https://www.businesswire.com/newsroom?industry=1050069)
- [Clinical Trials](https://www.businesswire.com/newsroom?industry=1000045)
- [Health Technology](https://www.businesswire.com/newsroom?industry=1778634)
- [Biotechnology](https://www.businesswire.com/newsroom?industry=1000039)
- [Health](https://www.businesswire.com/newsroom?industry=1000088)
- [Pharmaceutical](https://www.businesswire.com/newsroom?industry=1000146)
- [Science](https://www.businesswire.com/newsroom?industry=1050101)
[](https://www.vrtx.com/)
### Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20260120813466/en/Vertex-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-12th)
* * *
### Contacts
**Vertex Pharmaceuticals Incorporated Investor Relations:**
[investorinfo@vrtx.com](mailto:investorinfo@vrtx.com)
Social Media Profiles
[@VertexPharma](https://twitter.com/vertexpharma)
More News From Vertex Pharmaceuticals Incorporated
Get RSS Feed
[**Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3**](https://www.businesswire.com/news/home/20260217188901/en/Vertex-to-Participate-in-TD-Cowen-46th-Annual-Health-Care-Conference-on-March-3)
BOSTON--( [BUSINESS WIRE](https://www.businesswire.com/))--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast...
[**Vertex Reports Fourth Quarter and Full Year 2025 Financial Results**](https://www.businesswire.com/news/home/20260212596146/en/Vertex-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results)
BOSTON--( [BUSINESS WIRE](https://www.businesswire.com/))--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial guidance. “2025 marked a year of strong revenue growth, commercial diversification, and pipeline advancement,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our focus in 2026 remains on executing across the CF franchise, bringing CASGEVY...
[**Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings**](https://www.businesswire.com/news/home/20260111805110/en/Vertex-Provides-Pipeline-and-Business-Updates-in-Advance-of-Upcoming-Investor-Meetings)
BOSTON--( [BUSINESS WIRE](https://www.businesswire.com/))--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Ke...
[Back to Newsroom](https://www.businesswire.com/newsroom)
[](https://www.vrtx.com/)
### Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20260120813466/en/Vertex-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-12th)
* * *
### Contacts
**Vertex Pharmaceuticals Incorporated Investor Relations:**
[investorinfo@vrtx.com](mailto:investorinfo@vrtx.com)
Social Media Profiles
[@VertexPharma](https://twitter.com/vertexpharma)
## Wish your news had this kind of reach?
[Sign Up](https://www.businesswire.com/sign-up/account) [Learn About Business Wire](https://www.businesswire.com/why-business-wire)